R
Ralph B. D'Agostino
Researcher at Wake Forest University
Publications - 1336
Citations - 250792
Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.
Papers
More filters
Journal ArticleDOI
A Suggestion for Using Powerful and Informative Tests of Normality
TL;DR: For testing that an underlying population is normally distributed the skewness and kurtosis statistics, √b 1 and b 2, and the D'Agostino-Pearson K 2 statistic that combines these two statistics have been shown to be powerful and informative tests.
Journal ArticleDOI
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Anne L. Taylor,Susan Ziesche,Clyde W. Yancy,Peter E. Carson,Ralph B. D'Agostino,Keith C. Ferdinand,Malcolm Taylor,Kirkwood F. Adams,Michael L. Sabolinski,Manuel Worcel,Jay N. Cohn +10 more
TL;DR: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Journal ArticleDOI
The Prevention and Treatment of Missing Data in Clinical Trials
Roderick J. A. Little,Ralph B. D'Agostino,Michael L. Cohen,Kay Dickersin,Scott S. Emerson,John T. Farrar,Constantine Frangakis,Joseph W. Hogan,Geert Molenberghs,Susan A. Murphy,James D. Neaton,Andrea Rotnitzky,Daniel O. Scharfstein,Weichung Joe Shih,Jay P. Siegel,Hal S. Stern +15 more
TL;DR: Methods for preventing missing data and, failing that, dealing with data that are missing in clinical trials are reviewed.
Journal ArticleDOI
Lifetime Risk for Developing Congestive Heart Failure The Framingham Heart Study
Donald M. Lloyd-Jones,Martin G. Larson,Martin G. Larson,Eric P. Leip,Alexa S. Beiser,Ralph B. D'Agostino,William B. Kannel,William B. Kannel,Joanne M. Murabito,Joanne M. Murabito,Ramachandran S. Vasan,Ramachandran S. Vasan,Emelia J. Benjamin,Emelia J. Benjamin,Daniel Levy,Daniel Levy +15 more
TL;DR: The lifetime risk for developing overt CHF is 1 in 5 for both men and women and for CHF occurring in the absence of myocardial infarction, which highlights the risk of CHF that is largely attributable to hypertension.
Journal ArticleDOI
Fibrinogen and risk of cardiovascular disease. The Framingham Study.
TL;DR: The impact of fibrinogen value, considered as a separate variable, on cardiovascular disease was comparable with the major risk factors, such as blood pressure, hematocrit, adiposity, cigarette smoking, and diabetes and was significantly related to these risk factors.